-
1
-
-
0032722639
-
The hemophilias: progress and problems
-
Mannucci PM, Tuddenham EG. The hemophilias: progress and problems. Semin Hematol 1999; 36: 104-17.
-
(1999)
Semin Hematol
, vol.36
, pp. 104-117
-
-
Mannucci, P.M.1
Tuddenham, E.G.2
-
2
-
-
79955135530
-
-
Guide for the assessment of clotting factor concentrates. Available from: Regulatory-Guide-2008.pdf.Last updated
-
Farrugia A. Guide for the assessment of clotting factor concentrates. Available from: Regulatory-Guide-2008.pdf.Last updated: 2008.
-
(2008)
-
-
Farrugia, A.1
-
3
-
-
0033220609
-
Treatment of patients with inhibitors: cost issues
-
Goudemand J. Treatment of patients with inhibitors: cost issues. Haemophilia 1999; 5: 397-401.
-
(1999)
Haemophilia
, vol.5
, pp. 397-401
-
-
Goudemand, J.1
-
4
-
-
4644334185
-
Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction
-
Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
-
(2004)
Am J Hematol
, vol.77
, pp. 187-193
-
-
Leissinger, C.A.1
-
5
-
-
33751014075
-
Genetic risk factors for inhibitors to factors VIII and IX
-
Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12(Suppl 6): 15-22.
-
(2006)
Haemophilia
, vol.12
, Issue.SUPPL. 6
, pp. 15-22
-
-
Oldenburg, J.1
Pavlova, A.2
-
6
-
-
0016853978
-
Proceedings: a more uniform measurement of factor VIII inhibitors
-
Kasper CK, Aledort L, Aronson D et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
-
(1975)
Thromb Diath Haemorrh
, vol.34
, pp. 612
-
-
Kasper, C.K.1
Aledort, L.2
Aronson, D.3
-
7
-
-
11044235586
-
Inhibitors in haemophilia: clinical aspects
-
Di Michele D, Rivard G, Hay C et al. Inhibitors in haemophilia: clinical aspects. Haemophilia 2004; 10(Suppl 4): 140-5.
-
(2004)
Haemophilia
, vol.10
, Issue.SUPPL. 4
, pp. 140-145
-
-
Di Michele, D.1
Rivard, G.2
Hay, C.3
-
8
-
-
0141482007
-
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group
-
Gringeri A, Mantovani L.G, Scalone L et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2009; 102: 2358-63.
-
(2009)
Blood
, vol.102
, pp. 2358-2363
-
-
Gringeri, A.1
Mantovani, L.G.2
Scalone, L.3
-
9
-
-
84949470041
-
Immune tolerance: high-dose regimen
-
Rodrigues-Merchan EC, Lee CA eds., 1st edn. Oxford: Blackwell Science
-
Brackmann HH, Wallny T. Immune tolerance: high-dose regimen. In: Rodrigues-Merchan EC, Lee CA eds. Inhibitors in Patients with Haemophilia, 1st edn. Oxford: Blackwell Science, 2002: 45-8.
-
(2002)
Inhibitors in Patients with Haemophilia
, pp. 45-48
-
-
Brackmann, H.H.1
Wallny, T.2
-
10
-
-
37749001670
-
von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report
-
Federici AB, Mannucci PM, Marco P. von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report. Haemophilia 2008; 14: 133-9.
-
(2008)
Haemophilia
, vol.14
, pp. 133-139
-
-
Federici, A.B.1
Mannucci, P.M.2
Marco, P.3
-
11
-
-
0034284456
-
Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper
-
Colowick AB, Bohn RL, Avorn J et al. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
-
(2000)
Blood
, vol.96
, pp. 1698-1702
-
-
Colowick, A.B.1
Bohn, R.L.2
Avorn, J.3
-
12
-
-
33750974213
-
Immune tolerance: critical issues of factor dose, purity and treatment complications
-
DiMichele DM. Immune tolerance: critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12(Suppl 6): 81-5.
-
(2006)
Haemophilia
, vol.12
, Issue.SUPPL. 6
, pp. 81-85
-
-
DiMichele, D.M.1
-
13
-
-
41749124711
-
Immune tolerance and choice of concentrates
-
Rodrigues-Merchan EC, Lee CA eds., 1st edn. Oxford: Blackwell Science Ltd
-
Kreuz W. Immune tolerance and choice of concentrates. In: Rodrigues-Merchan EC, Lee CA eds. Inhibitors in Patients with Haemophilia, 1st edn. Oxford: Blackwell Science Ltd, 2002: 55-8.
-
(2002)
Inhibitors in Patients with Haemophilia
, pp. 55-58
-
-
Kreuz, W.1
-
14
-
-
79955135734
-
-
European Medicines Agency. Assessing the efficacy and safety of human plasma derived factor VIII:C and factor IX:C products in clinical trials in haemophiliacs before and after authorisation. Report No.: CPMP/BPWP/198/95.
-
European Medicines Agency. Assessing the efficacy and safety of human plasma derived factor VIII:C and factor IX:C products in clinical trials in haemophiliacs before and after authorisation. 2009. Report No.: CPMP/BPWP/198/95.
-
(2009)
-
-
-
15
-
-
0028837315
-
The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability
-
Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
-
(1995)
Thromb Haemost
, vol.73
, pp. 247-251
-
-
Verbruggen, B.1
Novakova, I.2
Wessels, H.3
-
16
-
-
0025847974
-
The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis
-
Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991; 66: 384-6.
-
(1991)
Thromb Haemost
, vol.66
, pp. 384-386
-
-
Morfini, M.1
Lee, M.2
Messori, A.3
-
17
-
-
0036249147
-
Inhibitor development in correlation to factor VIII genotypes
-
Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8(Suppl 2): 23-9.
-
(2002)
Haemophilia
, vol.8
, Issue.SUPPL. 2
, pp. 23-29
-
-
Oldenburg, J.1
El-Maarri, O.2
Schwaab, R.3
-
18
-
-
0029617930
-
Haemophilia A: mutation type determines risk of inhibitor formation
-
Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
-
(1995)
Thromb Haemost
, vol.74
, pp. 1402-1406
-
-
Schwaab, R.1
Brackmann, H.H.2
Meyer, C.3
-
19
-
-
0037314020
-
Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries
-
Albert T, Lange S, Oldenburg J et al. Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries. Hamostaseologie 2003; 23: 13-7.
-
(2003)
Hamostaseologie
, vol.23
, pp. 13-17
-
-
Albert, T.1
Lange, S.2
Oldenburg, J.3
-
20
-
-
33646140127
-
Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia
-
Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12(Suppl 3): 52-60.
-
(2006)
Haemophilia
, vol.12
, Issue.SUPPL. 3
, pp. 52-60
-
-
Astermark, J.1
-
21
-
-
79955165131
-
-
European Medicines Agency. Guideline on the investigation of human plasma-derived factor VIII and IX products. London; Report No.: CPMP/BPWG/198/95 rev.2.
-
European Medicines Agency. Guideline on the investigation of human plasma-derived factor VIII and IX products. London; 2007. Report No.: CPMP/BPWG/198/95 rev.2.
-
(2007)
-
-
-
22
-
-
30344434999
-
Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A
-
Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
-
(2006)
Blood
, vol.107
, pp. 46-51
-
-
Goudemand, J.1
Rothschild, C.2
Demiguel, V.3
-
23
-
-
33645963964
-
Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction
-
Hodge G, Saxon B, Revesz T. Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction. Haemophilia 2006; 12: 133-9.
-
(2006)
Haemophilia
, vol.12
, pp. 133-139
-
-
Hodge, G.1
Saxon, B.2
Revesz, T.3
-
24
-
-
0034917040
-
von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients
-
Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2008; 7: 375-80.
-
(2008)
Haemophilia
, vol.7
, pp. 375-380
-
-
Kallas, A.1
Talpsep, T.2
-
25
-
-
0038383605
-
The epidemiology of inhibitors in haemophilia A: a systematic review
-
Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
-
(2003)
Haemophilia
, vol.9
, pp. 418-435
-
-
Wight, J.1
Paisley, S.2
-
26
-
-
0034964673
-
Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients
-
Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38: 52-9.
-
(2001)
Semin Hematol
, vol.38
, pp. 52-59
-
-
Courter, S.G.1
Bedrosian, C.L.2
-
27
-
-
33751010515
-
Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development
-
Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006; 12(Suppl 6): 102-6.
-
(2006)
Haemophilia
, vol.12
, Issue.SUPPL. 6
, pp. 102-106
-
-
Ettingshausen, C.E.1
Kreuz, W.2
-
28
-
-
33846922841
-
Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A
-
Chalmers EA, Brown SA, Keeling D et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
-
(2007)
Haemophilia
, vol.13
, pp. 149-155
-
-
Chalmers, E.A.1
Brown, S.A.2
Keeling, D.3
-
29
-
-
34249690732
-
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
-
Gouw SC, van der Bom JG, van der Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
-
(2007)
Blood
, vol.109
, pp. 4648-4654
-
-
Gouw, S.C.1
van der Bom, J.G.2
van der Berg, H.M.3
-
30
-
-
33750983966
-
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors
-
Astermark J. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Haemophilia 2006; 12(Suppl 6): 8-13.
-
(2006)
Haemophilia
, vol.12
, Issue.SUPPL. 6
, pp. 8-13
-
-
Astermark, J.1
-
31
-
-
0034994489
-
Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age
-
Lorenzo JI, Lopez A, Altisent C et al. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-3.
-
(2001)
Br J Haematol
, vol.113
, pp. 600-603
-
-
Lorenzo, J.I.1
Lopez, A.2
Altisent, C.3
-
32
-
-
24944440876
-
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study
-
Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7.
-
(2005)
Br J Haematol
, vol.130
, pp. 422-427
-
-
Santagostino, E.1
Mancuso, M.E.2
Rocino, A.3
-
33
-
-
0029865410
-
Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies
-
Becker J, Schwaab R, Moller-Taube A et al. Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies. Am J Hum Genet 1996; 58: 657-70.
-
(1996)
Am J Hum Genet
, vol.58
, pp. 657-670
-
-
Becker, J.1
Schwaab, R.2
Moller-Taube, A.3
-
34
-
-
2542560221
-
The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients
-
Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
-
(2003)
Haematologica
, vol.88
-
-
Auerswald, G.1
Spranger, T.2
Brackmann, H.H.3
-
35
-
-
34249711370
-
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study
-
Gouw SC, van der Bom JG, Auerswald G et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7.
-
(2007)
Blood
, vol.109
, pp. 4693-4697
-
-
Gouw, S.C.1
van der Bom, J.G.2
Auerswald, G.3
|